Compare Stocks: ASRT, GYRE, AQST, and EOLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$3.80 -2.1%	$4.60	$2.93 ▼ $6.85	$486.99M	1.49	2.21 million shs	3.31 million shs
ASRT Assertio	$23.50	$23.42	$8.61 ▼ $23.50	$151.81M	0.52	271,083 shs	N/A
EOLS Evolus	$7.47 +1.4%	$7.89	$3.86 ▼ $9.31	$486.79M	1.38	698,632 shs	830,278 shs
GYRE Gyre Therapeutics	$4.43 -0.2%	$6.60	$4.26 ▼ $9.14	$495.10M	2.14	155,262 shs	256,353 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	-2.06%	-10.17%	-16.85%	-3.06%	-37.50%
ASRT Assertio	0.00%	0.00%	0.00%	0.00%	+116.03%
EOLS Evolus	+1.36%	-2.23%	0.00%	+0.81%	+16.54%
GYRE Gyre Therapeutics	-0.18%	-37.49%	-39.70%	-30.75%	-38.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$3.80 -2.1%	$4.60	$2.93 ▼ $6.85	$486.99M	1.49	2.21 million shs	3.31 million shs
ASRT Assertio	$23.50	$23.42	$8.61 ▼ $23.50	$151.81M	0.52	271,083 shs	N/A
EOLS Evolus	$7.47 +1.4%	$7.89	$3.86 ▼ $9.31	$486.79M	1.38	698,632 shs	830,278 shs
GYRE Gyre Therapeutics	$4.43 -0.2%	$6.60	$4.26 ▼ $9.14	$495.10M	2.14	155,262 shs	256,353 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	-2.06%	-10.17%	-16.85%	-3.06%	-37.50%
ASRT Assertio	0.00%	0.00%	0.00%	0.00%	+116.03%
EOLS Evolus	+1.36%	-2.23%	0.00%	+0.81%	+16.54%
GYRE Gyre Therapeutics	-0.18%	-37.49%	-39.70%	-30.75%	-38.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	2.60	Moderate Buy	$8.60	126.32% Upside
ASRT Assertio	1.80	Reduce	$22.65	-3.62% Downside
EOLS Evolus	2.50	Moderate Buy	$15.00	100.80% Upside
GYRE Gyre Therapeutics	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest ASRT, GYRE, AQST, and EOLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/5/2026	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$13.00 ➝ $15.00
10/16/2026	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
10/15/2026	AQST Aquestive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/6/2026	GYRE Gyre Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/11/2026	EOLS Evolus	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/10/2026	AQST Aquestive Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$11.00
8/25/2026	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$13.00
8/24/2026	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
8/18/2026	GYRE Gyre Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
8/7/2026	GYRE Gyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 11/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$54.09M	8.82	N/A	N/A	($0.28) per share	-13.57
ASRT Assertio	$118.71M	1.28	$0.02 per share	1,437.29	$14.63 per share	1.61
EOLS Evolus	$316.49M	1.56	N/A	N/A	($0.36) per share	-20.75
GYRE Gyre Therapeutics	$109.82M	4.50	$0.22 per share	19.98	$1.48 per share	2.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$83.78M	-$0.64	N/A	N/A	N/A	-162.33%	N/A	-54.84%	N/A
ASRT Assertio	-$30.38M	-$5.69	N/A	21.17	N/A	-34.94%	-38.72%	-13.32%	N/A
EOLS Evolus	-$51.64M	-$0.52	N/A	83.00	N/A	-10.85%	N/A	-13.00%	N/A
GYRE Gyre Therapeutics	$5.03M	-$0.21	N/A	N/A	N/A	-15.47%	-6.57%	-5.35%	11/6/2026 (Estimated)

Latest ASRT, GYRE, AQST, and EOLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	GYRE Gyre Therapeutics	-$0.15	N/A	N/A	N/A	$28.40 million	N/A
11/3/2026	Q3 2026	AQST Aquestive Therapeutics	-$0.12	-$0.13	-$0.01	-$0.13	$11.02 million	$7.56 million
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	-$0.18	-$0.0750	-$0.18	$11.42 million	$13.82 million
8/7/2026	Q2 2026	GYRE Gyre Therapeutics	-$0.0567	-$0.12	-$0.0633	-$0.12	$26.49 million	$29.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	7.19	6.74
ASRT Assertio	0.52	1.82	1.57
EOLS Evolus	N/A	1.70	1.28
GYRE Gyre Therapeutics	N/A	4.26	3.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
ASRT Assertio	48.96%
EOLS Evolus	90.69%
GYRE Gyre Therapeutics	23.99%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	6.81%
ASRT Assertio	5.70%
EOLS Evolus	5.00%
GYRE Gyre Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	147	125.51 million	116.97 million	Optionable
ASRT Assertio	20	6.46 million	6.09 million	Optionable
EOLS Evolus	353	66.05 million	62.75 million	Optionable
GYRE Gyre Therapeutics	618	111.51 million	100.92 million	Optionable

ASRT, GYRE, AQST, and EOLS Headlines

Recent News About These Companies

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - Time to Buy?

November 2 at 11:59 AM | marketbeat.com

Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down - Should You Sell?

October 30, 2026 | marketbeat.com

Gyre Therapeutics (GYRE) Set to Post Earnings on Friday

October 30, 2026 | americanbankingnews.com

Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Friday

October 30, 2026 | marketbeat.com

Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 8.9% - Here's Why

October 29, 2026 | marketbeat.com

Gyre Therapeutics (NASDAQ:GYRE) Shares Cross Above 200 Day Moving Average - Time to Sell?

October 29, 2026 | marketbeat.com

Gyre Therapeutics Announces CEO and CFO Compensation Agreements Effective October 2026

October 23, 2026 | kalkinemedia.comK

Gyre Therapeutics, Inc. enters into new employment agreements on October 16, 2026

October 22, 2026 | msn.com

H.C. Wainwright reiterates USD 18.00 target for Gyre Therapeutics stock

October 20, 2026 | ad-hoc-news.deA

Gyre Therapeutics stock falls 5.00 percent to USD 6.08 on October 16, 2026

October 18, 2026 | ad-hoc-news.deA

Gyre Therapeutics (NASDAQ:GYRE) Stock Rating Cut to Sell at Wall Street Zen

October 17, 2026 | marketbeat.com

Gyre Therapeutics (NASDAQ:GYRE) Upgraded at Zacks Research

October 8, 2026 | marketbeat.com

H.C. Wainwright keeps USD 18.00 target for Gyre Therapeutics stock

October 6, 2026 | ad-hoc-news.deA

Gyre Therapeutics stock gains 1.57 percent after upgrade

October 4, 2026 | ad-hoc-news.deA

Gyre Therapeutics stock holds steady as investors await next clinical and earnings milestones

September 21, 2026 | ad-hoc-news.deA

Gyre Therapeutics stock posts double digit 12 month gain as investors watch pipeline progress

September 21, 2026 | ad-hoc-news.deA

Gyre Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN)

August 12, 2026 | theglobeandmail.com

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2026 | zacks.com

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

August 7, 2026 | globenewswire.com

Gyre Therapeutics Appoints Three New Members to its Board of Directors

July 16, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, GYRE, AQST, and EOLS Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$3.80 -0.08 (-2.06%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$3.92 +0.12 (+3.16%)

As of 09:05 AM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Assertio NASDAQ:ASRT

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Evolus NASDAQ:EOLS

$7.47 +0.10 (+1.36%)

Closing price 11/4/2026 04:00 PM Eastern

Extended Trading

$7.28 -0.19 (-2.49%)

As of 09:25 AM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Gyre Therapeutics NASDAQ:GYRE

$4.43 -0.01 (-0.18%)

Closing price 11/4/2026 03:59 PM Eastern

Extended Trading

$4.50 +0.06 (+1.44%)

As of 09:25 AM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASRT, GYRE, AQST, and EOLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASRT, GYRE, AQST, and EOLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASRT, GYRE, AQST, and EOLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, GYRE, AQST, and EOLS Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Assertio NASDAQ:ASRT

Evolus NASDAQ:EOLS

Gyre Therapeutics NASDAQ:GYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASRT, GYRE, AQST, and EOLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASRT, GYRE, AQST, and EOLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASRT, GYRE, AQST, and EOLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, GYRE, AQST, and EOLS Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Assertio NASDAQ:ASRT

Evolus NASDAQ:EOLS

Gyre Therapeutics NASDAQ:GYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools